We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
+1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$3.17B
AUM Growth
+$561M
(+22%)
Cap. Flow
+$1.16B
Cap. Flow
% of AUM
36.62%
Top 10 Holdings %
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$37.9M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$24.5M |
| 3 |
Merck
MRK
|
+$12.3M |
| 4 |
Gilead Sciences
GILD
|
+$11.7M |
| 5 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$11.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Healthcare
ACHC
|
+$16.4M |
| 2 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$9.99M |
| 3 |
Tesla
TSLA
|
+$7.93M |
| 4 |
Larimar Therapeutics
LRMR
|
+$4.64M |
| 5 |
Ocular Therapeutix
OCUL
|
+$3.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 89.52% |
| 2 | Healthcare | 9.63% |
| 3 | Energy | 0.42% |
| 4 | Industrials | 0.14% |
| 5 | Consumer Staples | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGMO
26
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $15.5M | 0.49% |
10,168
+156
| +2% | +$1.89K |
|
27
PUT
Bristol-Myers Squibb
BMY
$130B
| $13.9M | 0.44% |
2,359
| – | – |
|
28
CALL
Agilent Technologies
A
$42.4B
| $13.7M | 0.43% |
3,337
-3,696
| -53% | -$149K |
|
|
AUXL
29
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $13.6M | 0.43% |
3,964
+117
| +3% | +$3.82K |
|
30
AstraZeneca
AZN
$252B
| $13.5M | 0.43% |
192,055
-23,268
| -11% | -$1.67M |
|
|
IOC
31
DELISTED
Interoil Corporation
IOC
| $13.2M | 0.42% |
270,330
+46,351
| +21% | +$2.48M |
|
|
BLUE
32
CALL
DELISTED
bluebird bio
BLUE
| $12.6M | 0.4% |
106
+29
| +38% | +$19.4K |
|
|
ACHN
33
DELISTED
Achillion Pharmaceuticals
ACHN
| $12.3M | 0.39% |
1,004,187
+946,216
| +1,632% | +$11.6M |
|
|
34
Merck
MRK
$355B
| $12M | 0.38% |
+221,264
| New | +$12.3M |
|
35
PUT
Biogen
BIIB
$31.9B
| $11.1M | 0.35% |
327
| – | – |
|
|
36
Gilead Sciences
GILD
$181B
| $10.7M | 0.34% |
+113,260
| New | +$11.7M |
|
37
PUT
MannKind Corp
MNKD
$1.14B
| $9.84M | 0.31% |
3,773
-1,337
| -26% | -$37.8K |
|
38
CALL
Sarepta Therapeutics
SRPT
$2.19B
| $9.51M | 0.3% |
6,572
+2,998
| +84% | +$50.8K |
|
39
CALL
Amgen
AMGN
$203B
| $9.24M | 0.29% |
580
-523
| -47% | -$81.5K |
|
40
Tenax Therapeutics
TENX
$68.5M
| $9.03M | 0.29% |
73
-15
| -17% | -$1.82M |
|
|
CBST
41
CALL
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $8.79M | 0.28% |
+873
| New | +$67.9K |
|
42
CALL
Danaher
DHR
$147B
| $8.57M | 0.27% |
+1,488
| New | +$80.7K |
|
|
43
PUT
Danaher
DHR
$147B
| $8.57M | 0.27% |
+1,488
| New | +$80.7K |
|
44
PUT
Teva Pharmaceuticals
TEVA
$45.5B
| $8.52M | 0.27% |
1,481
+65
| +5% | +$3.62K |
|
45
PUT
Community Health Systems
CYH
$417M
| $8.5M | 0.27% |
+1,908
| New | +$81.6K |
|
|
46
CALL
Merck
MRK
$355B
| $8.39M | 0.27% |
1,548
-5,075
| -77% | -$283K |
|
|
MBLY
47
PUT
DELISTED
Mobileye N.V.
MBLY
| $8.35M | 0.26% |
+2,058
| New | +$96.6K |
|
48
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
| $8.34M | 0.26% |
+923
| New | +$76.8K |
|
|
CARM
49
DELISTED
Carisma Therapeutics
CARM
| $8.29M | 0.26% |
34,874
+33,874
| +3,387% | +$7.6M |
|
50
PUT
Puma Biotechnology
PBYI
$480M
| $7.87M | 0.25% |
416
+182
| +78% | +$40.4K |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q4 2014 Portfolio in Review
As of Q4 2014, Sabby Management held 323 positions worth $3.17B, up 22% from $2.6B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Sabby Management deployed $1.16B of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1M.
By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 92% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.
- Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1M.
- Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
- Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
- Sabby Management fully exited Acadia Healthcare in Q4 2014, selling an estimated $16.4M.
- Sabby Management's ten largest holdings make up 63% of its $3.17B portfolio in Q4 2014.
- Sabby Management opened 68 new positions and closed 84 in Q4 2014.
- Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17B.
Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.